Sildenafil Tablet, Film Coated
Product Images NDC 50090-5235

11 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-5235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafilchemicalstructure (Sildenafilchemicalstructure)

Sildenafilchemicalstructure (Sildenafilchemicalstructure)
Chemical structure of Sildenafil, a human prescription drug. The diagram shows the molecular arrangement of atoms and bonds representing Sildenafil's chemical composition.*
FDA Label Image

Sildenafilfig1 (Sildenafilfig1)

Sildenafilfig1 (Sildenafilfig1)
This line graph shows the change in systolic blood pressure (SBP) over time post dose (in hours) comparing Doxazosin combined with Placebo versus Doxazosin combined with Sildenafil 25 mg. The vertical axis represents change in SBP (mmHg), while the horizontal axis represents time post dose from 0 to 8 hours. Two lines depict the differing SBP changes between these treatment groups.*
FDA Label Image

Sildenafilfig2 (Sildenafilfig2)

Sildenafilfig2 (Sildenafilfig2)
A line graph showing the change in systolic blood pressure (SBP) in mmHg over time (hours) post-dose for two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 25 mg. The graph illustrates SBP changes from 0 to 8 hours with the Sildenafil combination generally showing a greater reduction in SBP compared to placebo.*
FDA Label Image

Sildenafilfig3 (Sildenafilfig3)

Sildenafilfig3 (Sildenafilfig3)
Line graph showing change in systolic blood pressure (SBP) in mmHg over time post dose in hours. It compares two groups: Doxazosin plus Placebo and Doxazosin plus Sildenafil 50 mg, with the latter showing a larger decrease in SBP at various time points up to 8 hours post dose.*
FDA Label Image

Sildenafilfig4 (Sildenafilfig4)

Sildenafilfig4 (Sildenafilfig4)
A line graph comparing the blood pressure changes (mmHg) over time (hours) after dosing with Doxazosin plus Sildenafil 100 mg versus Doxazosin plus placebo. The Y-axis shows mmHg changes, ranging from -50 to 40, and the X-axis shows time after dosing, ranging from 0 to 8.5 hours. Two lines represent the treatments, with Doxazosin plus Sildenafil showing a greater decrease in pressure than placebo over most of the timeframe.*
FDA Label Image

Sildenafilfig5 (Sildenafilfig5)

Sildenafilfig5 (Sildenafilfig5)
A line graph showing plasma concentration (ng/mL) of Sildenafil over time post-dose (hours). The graph tracks levels from 0 to 24 hours, peaking around 1 to 2 hours, then gradually declining. Data points are marked with circles, indicating levels for a commercial tablet formulation.*
FDA Label Image

Sildenafilfog6a (Sildenafilfog6a)

Sildenafilfog6a (Sildenafilfog6a)
A bar chart showing the percentage of patients at endpoint across categories labeled 0 to 5. Each category is represented by stacked bars of different shades corresponding to values from 0 to 5 in the legend. The vertical axis shows percentages from 0 to 80%, indicating distribution of patients at each endpoint percentage for the categories.*
FDA Label Image

Sildenafilfog6b (Sildenafilfog6b)

Sildenafilfog6b (Sildenafilfog6b)
A bar chart displaying the percentage distribution of patients at endpoint across different categories labeled 0 to 5. Each category has multiple bars indicating subgroups, with the y-axis representing the percentage of patients and the x-axis denoting the categories. A legend on the right identifies the subgroups by numbers 0 to 5 in shaded boxes.*
FDA Label Image

Sildenafilfig7 (Sildenafilfig7)

Sildenafilfig7 (Sildenafilfig7)
A bar chart showing the percentage of patients reporting improvement across different treatment groups. The groups include Placebo (24%), Sildenafil Tablets 25 mg (63%), Sildenafil Tablets 50 mg (74%), and Sildenafil Tablets 100 mg (82%). The y-axis represents percentage reporting improvement, and the x-axis lists the treatment groups with sample sizes. The chart notes an overall treatment p-value less than 0.0001.*
FDA Label Image
FDA Label Image

Label Image (Lbl500905235)

Label Image (Lbl500905235)
Sildenafil 25 mg film-coated tablets packaging label from A-S Medication Solutions. The label shows dosage form as oral tablets, with each film-coated tablet containing 25 mg of sildenafil. The package contains 10 tablets with storage instructions to keep between 68 to 77 degrees Fahrenheit. Manufacturer is Camber Pharma Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.